Stockscreener 앱 받기
6.18
0.40%
-0.025
시간 외 거래:
6.18
Uniqure N V 주식(QURE)의 최신 뉴스
(QURE) Investment Analysis - Stock Traders Daily
uniQure NV (LTS:0EE0) Enterprise Value : $-65.19 Mil (As of Nov. 16, 2024) - GuruFocus.com
uniQure FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Privium Fund Management B.V. Acquires 104,500 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade - Yahoo Finance
(QURE) On The My Stocks Page - Stock Traders Daily
uniQure FY2024 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
HC Wainwright Issues Positive Estimate for uniQure Earnings - MarketBeat
William Blair Issues Positive Estimate for uniQure Earnings - MarketBeat
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - cnhinews.com
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates - Yahoo Finance
QUREuniQure N.V. Latest Stock News & Market Updates - StockTitan
Cantor Fitzgerald Reaffirms "Overweight" Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
uniQure N.V. Reports Q3 2024 Progress and Financials - TipRanks
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Uniqure NV earnings beat by $0.11, revenue fell short of estimates - Investing.com Australia
UniQure: Q3 Earnings Snapshot - San Francisco Chronicle
uniQure NV Q3 2024 Earnings: EPS Loss of $0.91 Beats Estimates, Revenue of $2.3 Million Misses Expectations - GuruFocus.com
uniQure reports Q3 EPS (91c), consensus ($1.01) - TipRanks
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
uniQure's Breakthrough: Huntington's Trial Success, $435M Cash Runway Through 2027 | QURE Stock News - StockTitan
abrdn plc Buys 1,528,581 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Assenagon Asset Management S.A. Has $1.34 Million Stake in uniQure (NASDAQ:QURE) - MarketBeat
Multiple Insiders Sold uniQure Shares Presenting Weak Signs For Investors - Simply Wall St
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Pfizer Loses Hemophilia Gene Therapy Patent Row To UniQure - Law360
uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring - Seeking Alpha
State Street Corp's Strategic Reduction in uniQure NV Holdings - GuruFocus.com
How To Trade (QURE) - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded to Sell by StockNews.com - MarketBeat
uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell” - Defense World
uniQure N.V. (QURE) requires closer examination - US Post News
uniQure Initiates Trial for Promising ALS Gene Therapy - TipRanks
uniQure announces dosing of first patient in Phase I/II trial of AMT-162 - TipRanks
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - StockTitan
Raymond James gives an Outperform recommendation for uniQure N.V. (QURE) - Knox Daily
Ratios Uncovered: Breaking Down uniQure N.V. (QURE)’s Trailing Twelve Months Metrics - The Dwinnex
Marshall Wace LLP Invests $175,000 in uniQure (NASDAQ:QURE) - Defense World
uniQure shares coverage resumed on robust clinical portfolio - Investing.com
Raymond James Reiterates Outperform Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure shares coverage resumed on robust clinical portfolio By Investing.com - Investing.com UK
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
An analyst sees good growth prospects for uniQure N.V. (QURE) - SETE News
Market Recap: uniQure N.V. (QURE)’s Positive Momentum, Closing at 5.92 - The Dwinnex
The uniQure N.V. (QURE) had a good session last reading, didn’t it? - US Post News
uniQure N.V.’s Mixed Bag: Up 9.71% in 6 Months, Up 2.17% in 30 Days - The InvestChronicle
uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 10% this week, taking five-year losses to 89% - Simply Wall St
Technical analysis of uniQure N.V. (QURE) stock chart patterns - US Post News
uniQure (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sale Alert: uniQure N.V. [QURE] – Is it Time to sell? - Knox Daily
3.66%
1.11%
자본화:
|
볼륨(24시간):